Women's Health
Is Menopause Hormone Therapy Safe? What Changed in 2025
Updated November 18, 2026 · 7 min read
For healthy women under 60 or within 10 years of menopause with bothersome hot flashes and no reason to avoid estrogen, The Menopause Society says the benefits generally outweigh the risks, which it calls rare. In November 2025, FDA asked makers to drop cardiovascular disease, breast cancer and probable dementia from the boxed warning; clot, stroke and breast cancer warnings remain.
FDA notes that millions of women have avoided hormone therapy since the early 2000s out of fear; this is a real shift, but not a blanket all-clear. The Menopause Society says the risks differ by the type of hormone, the dose, how long you use it, how it is taken, when you start and whether a progestogen is needed. Here is what the evidence and the new labels say, and how menopause hormone therapy in Ocala begins at Padgett Medical Center.
What does menopause hormone therapy help with?
Hot flashes and night sweats above all. The Menopause Society's 2022 position statement calls hormone therapy the most effective treatment for them and for the genitourinary syndrome of menopause (vaginal dryness, pain with sex and related urinary symptoms), and says it has been shown to prevent bone loss and fracture. In the trials the statement cites, estrogen alone or with a progestogen cut weekly hot flash frequency by about 75% compared with placebo. That figure comes from research on approved prescription hormone therapy; it is not a promise for any one woman.
The statement lists four FDA-approved uses: moderate to severe hot flashes, moderate to severe vaginal and vulvar symptoms, preventing osteoporosis after menopause, and low estrogen caused by conditions such as removal of both ovaries or primary ovarian insufficiency.
Why do age and timing matter so much?
Because risk climbs with age. The Menopause Society finds the balance favorable for women under 60 or within 10 years of menopause onset, and less favorable for women who start later, because their absolute risks of coronary heart disease, stroke, blood clots and dementia are greater. In the Women's Health Initiative (WHI), the large long-term trials, starting hormones after age 70 carried the highest risk.
That gap drove FDA's rethink. The WHI trials that shaped the old warnings enrolled women aged 50 to 79, average age 63, while the average U.S. woman reaches menopause at 51 and bothersome hot flashes usually come between about 45 and 55, FDA noted. The WHI memory studies behind the dementia warning enrolled women 65 to 79. Updated labels for systemic products now ask prescribers to consider starting before 60 or within 10 years of menopause.
What did FDA change in 2025 and 2026?
On November 10, 2025, FDA asked the makers of every menopausal hormone therapy, systemic and vaginal products alike, to remove cardiovascular disease, breast cancer and probable dementia from the boxed warning, the agency's most prominent safety warning. It also asked them to drop endometrial cancer from the box except on systemic estrogen-alone products, to remove the advice to use the lowest effective dose for the shortest time, and to take the probable dementia warning out of the labels altogether.
On February 12, 2026, FDA approved the first updated labels, for six products covering all four types: combined estrogen and progestogen, estrogen alone, progestogen alone for women with a uterus who use estrogen, and vaginal estrogen. By then, 29 companies had submitted proposed changes. FDA pointed to underuse: about 2 million women aged 46 to 65 had a prescription in 2020, out of roughly 41 million U.S. women aged 45 to 64.
Which risks are still in the labels?
The serious ones moved out of the box; they did not disappear. FDA did not ask companies to remove cardiovascular disease or breast cancer from the Warnings and Precautions section of the labels. Systemic estrogen-alone products also keep a boxed warning: for a woman with a uterus, estrogen alone raises the risk of endometrial cancer, cancer of the uterine lining. That boxed warning adds that a progestogen has been shown to lower the risk of endometrial hyperplasia, an overgrowth of the lining that may come before that cancer.
The February 2026 label for one FDA-approved estradiol gel still warns about blood clots in the legs and lungs, stroke, breast cancer, ovarian cancer and gallbladder disease. Labels differ by product, so ask your provider to walk you through yours.
How big are the risks for women in their 50s?
Small, in absolute terms. The Menopause Society calls the added risks rare, meaning fewer than 10 extra cases per 10,000 women per year. For estrogen plus a progestogen, it puts breast cancer risk at less than one additional case per 1,000 women per year, or three per 1,000 over five years with the regimen the WHI tested, and compares that with the risk tied to two alcoholic drinks a day, obesity or low physical activity.
Estrogen alone looks different. According to the estradiol gel label, WHI women aged 50 to 59 without a uterus who took estrogen alone had about 4 more lung clots, 5 more leg clots, 1 fewer stroke and 5 fewer breast cancers per 10,000 women a year than women on placebo, and none of those differences was statistically significant. The label adds that only one oral estrogen at one dose was studied, so how its clot and stroke findings apply to other doses, routes and products is not known.
Duration matters, too. The same label reports a large analysis of observational studies in which women who used estrogen alone for 5 to 14 years had a 33% higher relative risk of breast cancer than women who never used it, and The Menopause Society notes that observational data show breast cancer risk rising with longer use of either type.
Does the type of hormone therapy change the risk?
Yes, though head-to-head trials are scarce. Estrogen alone and estrogen with a progestogen produced different breast cancer findings in the WHI, which is why The Menopause Society says longer use may be more favorable for estrogen alone. How it is taken may matter too: observational studies have not tied estrogen through the skin to blood clots, and limited data suggest less clot risk than with pills, but no randomized trial has compared them directly. ACOG likewise says patches, sprays and rings may pose less clot risk than pills.
The statement adds that lower doses and the type of progestogen may also affect clot risk. None of this means picking a form yourself; your provider decides with you.
Who should not take estrogen?
The February 2026 label for one FDA-approved estradiol gel rules it out for women with abnormal genital bleeding that has not been diagnosed; breast cancer now or in the past; another estrogen-dependent tumor; a blood clot in the legs or lungs, a stroke or a heart attack, now or in the past; liver disease; a known clotting disorder, such as protein C, protein S or antithrombin deficiency; or a past severe allergic reaction to the product. Its patient leaflet adds that it is not for pregnant women.
For breast cancer survivors, The Menopause Society says systemic hormone therapy is generally not advised, though it may be considered with their oncologist for severe hot flashes that non-hormone options have not relieved. The statement also says your own and your family's risk of heart disease, stroke, blood clots and breast cancer should be weighed before starting.
What should you watch for once you start?
Know the warning signs. The estradiol gel's patient leaflet says to call your healthcare provider right away for new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, severe pain in your chest or legs with or without shortness of breath, weakness and fatigue, or swelling of the face, lips and tongue.
Keep up with breast exams and mammograms, and, as ACOG recommends, review with your provider every year whether to continue. Never stop or change a dose on your own.
How does Padgett start hormone therapy in Ocala?
With your history and lab testing, not a prescription: your provider sets the plan from both. Your visit is with Sarah Weir, APRN, an advanced practice registered nurse, in the Ocala office at 200 SW 8th St., Suite A, or by telehealth anywhere in Florida while you are physically in the state. Expect questions about your periods or your last period, your symptoms and how much they bother you, your medicines, and your own and your family's history of clots, stroke, heart disease and cancer.
If hormone therapy fits, your provider explains the options and why one suits you; if it does not, other approaches are on the table. No treatment is promised in advance. Because the plan follows your labs, so does its cost; your provider goes over both with you before any prescription, and there is no contract to sign. Asking about bioidentical products? Read bioidentical hormones explained and see bioidentical hormone therapy for women in Ocala. Still sorting out your stage? Start with perimenopause vs. menopause: signs and tests, or browse the HRT program for men and women.
Questions before a visit? Ask for the free consultation online, and the team calls you back for a free 15-minute phone call with the medical staff; it is not a visit with the provider and nothing is prescribed on it. Or call the clinic at (352) 369-0104, Monday to Friday, 9:00 AM to 5:00 PM.
This article is educational and is not medical advice. Talk with a licensed provider about your own health, medications and treatment options.
Pending medical review. This article is educational and is not medical advice. Never start, stop, split or change the timing of a prescription based on something you read online. Your provider decides your dose and your schedule.
Frequently asked questions
Does a family history of breast cancer rule out hormone therapy?
Not automatically. The Menopause Society says observational evidence suggests hormone therapy does not further raise the relative risk of breast cancer in women with a family history. Because their starting risk is higher, though, the actual number of extra cases would be larger, so your provider weighs your family history carefully before recommending anything.
Is vaginal estrogen as risky as pills or patches?
Low-dose vaginal estrogen is treated differently. FDA asked makers to condense its safety information to what matters for a vaginal product, and the uterine cancer boxed warning now stays only on systemic estrogen-alone products. The Menopause Society says low-dose vaginal estrogen does not appear to raise uterine cancer risk, though those trials lasted only a year.
Do I still need mammograms while on hormone therapy?
Yes. The Menopause Society advises regular breast cancer screening for all postmenopausal women, including those on hormone therapy, and one estradiol gel's patient leaflet calls for a breast exam and mammogram every year unless your provider says otherwise. Some regimens make breast tissue look denser on a mammogram, which can lead to extra imaging.
Can hormone therapy protect my heart or memory?
It is not used for that. The Menopause Society says hormone therapy is not approved to prevent heart disease and is not recommended at any age to prevent memory decline or dementia. The patient leaflet for one FDA-approved estradiol gel agrees: do not use estrogen alone to prevent heart disease, heart attacks, strokes or dementia.
What side effects are common when starting hormone therapy?
The Menopause Society lists nausea, bloating, weight gain, fluid retention, headaches, breast tenderness and breakthrough bleeding, plus mood swings linked to progestogens. ACOG says spotting or bleeding usually stops within 6 months. Tell your provider about any effect that bothers you or lasts longer than expected, and don't adjust your dose yourself.
Sources
- FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies, U.S. Food and Drug Administration, November 10, 2025 (content current as of 02/12/2026)
- FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, U.S. Food and Drug Administration, February 12, 2026
- Hormone Replacement Therapies Can Help Women with Bothersome Menopausal Symptoms, U.S. Food and Drug Administration (content current as of 02/13/2026)
- The 2022 hormone therapy position statement of The North American Menopause Society (now The Menopause Society), Menopause 2022;29(7):767-794
- DIVIGEL (estradiol gel) prescribing information and patient information, revised 2/2026, DailyMed, U.S. National Library of Medicine
- Hormone Therapy for Menopause (FAQ517), American College of Obstetricians and Gynecologists, last reviewed February 2024
